Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma
✍ Scribed by Hee Kyung Kim; Young Lyun Oh; Seok-Hyung Kim; Dong Youn Lee; Ho-Cheol Kang; Ji In Lee; Hye Won Jang; Kyu Yeon Hur; Jae Hyeon Kim; Yong Ki Min; Jae Hoon Chung; Sun Wook Kim
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 322 KB
- Volume
- 34
- Category
- Article
- ISSN
- 1043-3074
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background
Parafibromin is a protein encoded by the HRPT2 oncosuppressor gene, and the expression is reported to be decreased or absent in parathyroid carcinomas.
Methods
A total of 26 tumor specimens from 18 patients with adenoma and 8 patients with carcinoma were immune‐stained with an antibody against parafibromin.
Results
Parafibromin immunostaining showed strong positivity in 17 of 18 adenomas. Negative staining was noted in 3 of 8 carcinomas, and weak positivity was found in 3 of 8 carcinomas. The remaining 2 cases of carcinoma showed strong positivity. The loss of parafibromin expression (negative or weak positivity) demonstrated 94.4% specificity in the diagnosis of parathyroid carcinomas. Relapses or distant metastases of carcinoma occurred only in cases in which there was a loss of parafibromin immunostaining.
Conclusions
Loss of parafibromin immunostating showed promising results in the differential diagnosis of parathyroid carcinoma from adenoma and may also serve as a prognostic marker. © 2011 Wiley Periodicals, Inc. Head Neck, 2012